Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

BACKGROUND: The optimal neoadjuvant regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly improved survival in patients with EGFR-mutant advanced NSCLC. However, their efficacy in neoadjuvant settings, particularly for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Liwen, Lou, Yuqing, Bai, Hao, Li, Rong, Xia, Jinjing, Fang, Wentao, Zhang, Jie, Han-Zhang, Han, Lizaso, Analyn, Li, Bing, Gu, Aiqin, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Prospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607055/
https://www.ncbi.nlm.nih.gov/pubmed/31885349
http://dx.doi.org/10.1177/0300060519887275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607055/
https://www.ncbi.nlm.nih.gov/pubmed/31885349
http://dx.doi.org/10.1177/0300060519887275

Ejemplares similares